Search Results

Tevogen Bio Holdings Inc. is set to join the broad-market Russell 3000® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, according to a preliminary list of additions posted Friday, May 24.

Tevogen Bio Holdings Inc. has announced financial results for the fiscal quarter ended March 31, 2024, and filed its quarterly report on Form 10-Q with the Securities and Exchange Commission.

Tevogen Bio Holdings Inc. reports publication of its phase I clinical trial data of TVGN 489, its investigational allogeneic SARS-CoV-2 specific Cytotoxic CD8+ T lymphocytes (CTLs) immunotherapy by the journal Blood Advances.

Tevogen Bio Holdings Inc. has entered into a binding term sheet [with an existing investor] to secure up to $50 million of financing.

Tevogen Bio Holdings Inc. announced financial results for full year 2023, business highlights, and upcoming operational objectives.

Tevogen Bio Holdings Inc. filed a Registration Statement on Form S-1 on June 21, 2024, to register the issuance of previously disclosed shares of the Company’s common stock as well as the resale of shares of common stock and warrants by existing securityholders.

Tevogen Bio Holdings Inc. has announced the completion of Tevogen Bio Inc’s previously announced business combination with Semper Paratus Acquisition Corporation, leading to the formation of Tevogen Bio Holdings Inc.

Tevogen Bio Holdings Inc., a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in oncology, neurology, and virology, following the recent elimination of $94.9 million in balance sheet liabilities, has entered into a definitive agreement for up to $50 million in financing.